Holen Sie sich die Stockscreener-App
26.13
2.63%
0.67
Schlusskurs vom Vortag:
$25.46
Offen:
$25.44
24-Stunden-Volumen:
1.33M
Relative Volume:
0.88
Marktkapitalisierung:
$1.69B
Einnahmen:
$32.08M
Nettoeinkommen (Verlust:
$-169.77M
KGV:
-9.1949
EPS:
-2.8418
Netto-Cashflow:
$-147.70M
1W Leistung:
+1.75%
1M Leistung:
+2.47%
6M Leistung:
-21.60%
1J Leistung:
-17.39%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$24.52
$26.72
52-Wochen-Spanne:
$20.32
$40.22
Stoke Therapeutics Inc Stock (STOK) Company Profile
Firmenname
Stoke Therapeutics Inc
Sektor
Branche
Telefon
781-430-8200
Adresse
45 WIGGINS AVENUE, BEDFORD, MA
Compare STOK vs VRTX, REGN, MRNA, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
STOK
Stoke Therapeutics Inc
|
26.13 | 1.69B | 32.08M | -169.77M | -147.70M | -2.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Stoke Therapeutics Inc Stock (STOK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-08-21 | Fortgesetzt | JP Morgan | Overweight |
| 2026-07-13 | Eingeleitet | Goldman | Buy |
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2026-02-05 | Eingeleitet | Guggenheim | Buy |
| 2026-01-05 | Fortgesetzt | Chardan Capital Markets | Buy |
| 2025-07-18 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-03-26 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-07-25 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-05-01 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-04-26 | Fortgesetzt | Canaccord Genuity | Buy |
| 2023-01-06 | Herabstufung | BofA Securities | Buy → Underperform |
| 2022-10-24 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-01-31 | Eingeleitet | Jefferies | Buy |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-11-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-18 | Eingeleitet | UBS | Neutral |
| 2021-05-10 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-02-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-12-11 | Bestätigt | Needham | Buy |
| 2020-10-23 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-09-29 | Fortgesetzt | JP Morgan | Neutral |
| 2020-09-29 | Eingeleitet | Needham | Buy |
| 2019-12-18 | Eingeleitet | Wedbush | Outperform |
| 2019-11-12 | Eingeleitet | BTIG Research | Buy |
| 2019-10-25 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-15 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-07-15 | Eingeleitet | Cowen | Outperform |
| 2019-07-15 | Eingeleitet | Credit Suisse | Outperform |
| 2019-07-15 | Eingeleitet | JP Morgan | Overweight |
Alle ansehen
Stoke Therapeutics Inc Aktie (STOK) Neueste Nachrichten
Form 144 STOKE THERAPEUTICS For: 21 October By Investing.com - Investing.com Canada
A former affiliate plans to exercise options without cash and sell Stoke Therapeutics (STOK) shares. - Stock Titan
Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.25 - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Business Wire
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Form 4 Stoke Therapeutics Inc: Barry Ticho (CHIEF MEDICAL OFFICER) For: 1 October By Investing.com - Investing.com South Africa
Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October - Investing.com India
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock By Investing.com - Investing.com Nigeria
Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October - Investing.com Nigeria
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock By Investing.com - Investing.com Canada
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock - Investing.com
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock - Investing.com
Form 4 Stoke Therapeutics Inc: Jonathan Allan (GENERAL COUNSEL & CORP SEC) For: 2 October - Investing.com UK
Stoke therapeutics general counsel Jonathan Allan sells $16,508 stock By Investing.com - Investing.com UK
Stoke therapeutics CMO Barry Ticho sells $27,493 in stock By Investing.com - Investing.com UK
Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
Stoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting - Business Wire
At $26.33 a share, Jonathan Allan sells 627 shares of Stoke Therapeutics (STOK). - Stock Titan
Officer Jonathan D. Allan proposes selling 627 shares of Stoke Therapeutics (STOK). - Stock Titan
Under a trading plan, Stoke Therapeutics (STOK) medical chief sells 1,051 shares. - Stock Titan
BVF Partners Reveals 5.6% Ownership Stake in Stoke Therapeutics Inc. (NASDAQ:STOK) - kalkinemedia.com
A passive stake at Stoke Therapeutics (STOK) includes 76,938 shares in a managed account. - Stock Titan
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com Nigeria
Form 4 Stoke Therapeutics Inc For: 26 September By Investing.com - Investing.com Australia
Stoke Therapeutics (STOK) grants director Alexander Cumbo options priced at $26.11 per share. - Stock Titan
Why Is Stoke Therapeutics, Inc. (STOK) Suddenly a Must-Watch Growth Stocks Name? - Kalkine Media
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - Yahoo Finance
Stoke Therapeutics Stock Price Forecast. Should You Buy STOK? - StockInvest.us
Encoded Therapeutics Raises $275 Million to Advance Dravet Syndrome Gene Therapy - finance.biggo.com
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Nigeria
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com Canada
Goldman Sachs reiterates Stoke Therapeutics stock rating on Dravet study confidence - Investing.com India
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com India
Stoke Therapeutics at Cantor conference: dravet data, cash runway By Investing.com - Investing.com Canada
STOK: Phase III data for Dravet syndrome and strong OLE results position the pipeline for major milestones - TradingView
STOK: Phase III Dravet therapy shows durable 75%+ seizure reduction and functional gains in long-term data - TradingView
Stoke Therapeutics (STOK) Institutional Ownership 2026 $STOK - MarketBeat
Legal & General Group Plc Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics, Inc. $STOK Shares Sold by Troluce Capital Advisors LLC - MarketBeat
Bank of New York Mellon Corp Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Stoke Therapeutics and Biogen Present Long-Term Clinical Data tha - The National Law Review
Stoke Therapeutics CMO Barry Ticho Executes 5,545 Share Sales Under 10b5-1 Plan - Kalkine Media
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - manilatimes.net
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) - Biogen
Biogen Inc. - Via Ritzau
Stoke Therapeutics (NASDAQ:STOK) Insider Sells $170,065.15 in Stock - MarketBeat
Stoke Therapeutics (STOK) CMO sells 5,545 shares under pre-set plan - Stock Titan
Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation - Moomoo
The Manufacturers Life Insurance Company Makes New Investment in Stoke Therapeutics, Inc. $STOK - MarketBeat
Finanzdaten der Stoke Therapeutics Inc-Aktie (STOK)
Umsatz
Nettogewinn
Free Cashflow
ENV
Stoke Therapeutics Inc-Aktie (STOK) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Oct 02 '26 |
Sale |
26.33 |
627 |
16,509 |
20,598 |
| JONATHAN D ALLAN | Officer |
Oct 02 '26 |
Proposed Sale |
26.01 |
627 |
16,308 |
0 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Oct 01 '26 |
Sale |
26.16 |
1,051 |
27,494 |
19,059 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Sep 01 '26 |
Sale |
30.67 |
5,545 |
170,061 |
20,110 |
| Kaye Edward M. MD | Director |
Aug 18 '26 |
Sale |
32.03 |
12,567 |
402,528 |
124,557 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 18 '26 |
Sale |
32.03 |
2,861 |
91,639 |
21,225 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Aug 18 '26 |
Sale |
32.03 |
4,767 |
152,690 |
25,655 |
| Allan Jonathan | GENERAL COUNSEL & CORP SEC |
Aug 14 '26 |
Option Exercise |
0.00 |
6,000 |
0 |
24,086 |
| Kaye Edward M. MD | Director |
Aug 14 '26 |
Option Exercise |
0.00 |
26,250 |
0 |
137,124 |
| Ticho Barry | CHIEF MEDICAL OFFICER |
Aug 14 '26 |
Option Exercise |
0.00 |
10,000 |
0 |
30,422 |
12.15%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):